secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001723128-25-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance
--------------------------------------------------------------------------------

- Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.
- Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).
- Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.
- Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.
- Launched BREKIYA autoinjector for migraine in October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/0001723128-25-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/amrx-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001723128-25-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer